

A. FURTHER INFORMATION ABOUT OUR GROUP**1. Incorporation of Our Company**

Our Company was established as a limited liability company in the PRC on December 14, 2010 and converted into a joint stock company with limited liability on August 27, 2020.

As of the date of this prospectus, our Company's head office is located at Unit 101, Building A3, Biological Nano Park, No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, the PRC. Our Company has established a principal place of business in Hong Kong at 40/F, Sunlight Tower, 248 Queen's Road East, Wanchai, Hong Kong and has been registered as a non-Hong Kong company under Part 16 of the Companies Ordinance on September 18, 2020 with the Registrar of Companies in Hong Kong. Mr. Lok Kwan YIM has been appointed as the authorized representative of our Company for the acceptance of service of process in Hong Kong. The address for service of process is 40/F, Sunlight Tower, 248 Queen's Road East, Wanchai, Hong Kong.

As our Company was established in the PRC, our corporate structure and Articles of Association are subject to the relevant laws and regulations of the PRC. A summary of the relevant provisions of our Articles of Association is set out in "Appendix V—Summary of Articles of Association." A summary of certain relevant aspects of the laws and regulations of the PRC is set out in "Appendix IV—Summary of Principal Legal and Regulatory Provisions."

2. Changes in Share Capital of Our Company

Save as disclosed in the section headed "History and Corporate Structure", there has been no alteration in the share capital of our Company since its incorporation.

3. Shareholders' Resolutions

At the extraordinary general meeting of our Company held on August 31, 2020, among other things, the following resolutions were passed by the Shareholders:

- (a) the issue by our Company of H Shares of nominal value of RMB1.00 each and such H Shares be listed on the Stock Exchange;
- (b) the number of H Shares to be issued before the exercise of the Over-allotment Option shall not exceed 66,667,000 H Shares, representing approximately 25% of the enlarged share capital of our Company upon completion of the Global Offering and granting the Underwriters the Over-allotment Option of no more than 15% of the above number of H Shares to be issued pursuant to this resolution;
- (c) subject to the completion of the Global Offering, the conditional adoption of the Articles of Association, which shall become effective on Listing Date; and

- (d) authorization of the Board and its authorized persons to handle all matters relating to, among other things, the Global Offering, the issue and listing of the H Shares.

4. Changes in Share Capital of Our Subsidiaries

Details of the subsidiaries of our Company are set out in “Appendix I—Accountants’ Report.”

- (a) On November 30, 2018, the registered capital of Basecare Medical Device was increased from RMB50 million to RMB70 million.
- (b) On February 27, 2019, the registered capital of Basecare Medical Device was increased from RMB70 million to RMB100 million.
- (c) On March 4, 2020, the registered capital of Basecare Medical Device was increased from RMB100 million to RMB130 million.
- (d) On April 10, 2019, Basecare Intelligent Manufacturing was established in the PRC with a registered capital of RMB1 million.

Save as disclosed above and in the section headed “History and Corporate Structure”, there has been no alteration in the share capital of the subsidiaries of our Company within two years immediately preceding the date of this prospectus.

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contracts

The following contracts (not being contracts entered into in the ordinary course of business) have been entered into by us or any of our subsidiaries within the two years preceding the date of this prospectus that are or may be material:

- (a) a series C+ equity transfer agreement (C+輪股權轉讓協議) dated July 8, 2020 entered into among Jiangsu Double Helix Biology Science and Technology Co., Ltd. (江蘇雙螺旋生物科技有限公司), Liang Bo (梁波), Suzhou Basecare Investment Management Enterprise (Limited Partnership) (蘇州貝康投資管理企業(有限合夥)), Guangzhou Darui Biotechnology Co., Ltd. (廣州市達瑞生物技術股份有限公司), Suzhou Industrial Park Seed Zhengze Yihao Venture Capital Enterprise (Limited Partnership) (蘇州工業園區原點正則壹號創業投資企業(有限合夥)), Suzhou Industrial Park Sungen Bio-Venture Capital Investment Enterprise (Limited Partnership) (蘇州工業園區新建元生物創業投資企業(有限合夥)), HH SPR-XIV HK Holdings Limited, Zhangjiagang Broad Vision Harmony Shareholding Investment Fund (Limited Partnership) (張家港博華和瑞股權投資合夥企業(有限合夥)) and ORBIMED PARTNERS MASTER FUND LIMITED;

- (b) a series D financing agreement (D輪融資協議) dated July 23, 2020 entered into among Jiangsu Double Helix Biology Science and Technology Co., Ltd. (江蘇雙螺旋生物科技有限公司), Liang Bo (梁波), Guangzhou DaAn Gene Technology Co., Ltd (廣州市達安基因科技有限公司), Guangzhou Darui Biotechnology Co., Ltd. (廣州市達瑞生物技術股份有限公司), Suzhou Basecare Investment Management Enterprise (Limited Partnership) (蘇州貝康投資管理企業(有限合夥)), Suzhou Industrial Park Seed Zhengze Yihao Venture Capital Enterprise (Limited Partnership) (蘇州工業園區原點正則壹號創業投資企業(有限合夥)), Zhejiang Shuangjing Investment Co., Ltd (浙江雙井投資有限公司), Suzhou Industrial Park Sungent Bio-Venture Capital Investment Enterprise (Limited Partnership) (蘇州工業園區新建元生物創業投資企業(有限合夥)), Beijing Zhongcheng Fangyuan Phase II Investment Center (Limited Partnership) (北京中誠方圓二期投資中心(有限合夥)), Guangzhou DaAn Jinghan Medical Health Industry Investment Enterprise (Limited Partnership) (廣州達安京漢醫療健康產業投資企業(有限合夥)), Zhangjiagang Broad Vision Investment Fund (Limited Partnership) (張家港博華創業投資合夥企業(有限合夥)), Suzhou MING Bioventures Fund I Venture Capital, L.P. (蘇州聚明中泓方仁創業投資合夥企業(有限合夥)), Yingtian Jinhu Jiayi Hongsheng Investment Management Limited Partnership Corporation (鷹潭金虎嘉怡弘晟投資管理有限合夥企業), HH SPR-XIV HK Holdings Limited; Zhangjiagang Broad Vision Harmony Shareholding Investment Fund (Limited Partnership) (張家港博華和瑞股權投資合夥企業(有限合夥)) and ORBIMED PARTNERS MASTER FUND LIMITED;
- (c) a cornerstone investment agreement dated January 21, 2021 entered into among the Company, CLSA Capital Markets Limited (中信里昂證券資本市場有限公司), CLSA Limited (中信里昂證券有限公司), ORBIMED PARTNERS MASTER FUND LIMITED, THE BIOTECH GROWTH TRUST PLC, ORBIMED GENESIS MASTER FUND, L.P. and ORBIMED NEW HORIZONS MASTER FUND, L.P. pursuant to which ORBIMED PARTNERS MASTER FUND LIMITED, THE BIOTECH GROWTH TRUST PLC, ORBIMED GENESIS MASTER FUND, L.P. and ORBIMED NEW HORIZONS MASTER FUND, L.P. agreed to subscribe for H Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$20,000,000;
- (d) a cornerstone investment agreement dated January 21, 2021 entered into among the Company, CLSA Capital Markets Limited (中信里昂證券資本市場有限公司), CLSA Limited (中信里昂證券有限公司) and Affin Hwang Asset Management Berhad pursuant to which Affin Hwang Asset Management Berhad agreed to subscribe for H Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$10,000,000;
- (e) a cornerstone investment agreement dated January 21, 2021 entered into among the Company, CLSA Capital Markets Limited (中信里昂證券資本市場有限公司), CLSA Limited (中信里昂證券有限公司) and CRF INVESTMENT HOLDINGS COMPANY LIMITED pursuant to which CRF INVESTMENT HOLDINGS COMPANY LIMITED agreed to subscribe for H Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$20,000,000;

- (f) a cornerstone investment agreement dated January 21, 2021 entered into among the Company, CLSA Capital Markets Limited (中信里昂證券資本市場有限公司), CLSA Limited (中信里昂證券有限公司), Foresight Orient Global Superior Choice SPC – Global Superior Choice Fund 1 SP and Foresight Orient Global Superior Choice SPC – Vision Fund 1 SP pursuant to which Foresight Orient Global Superior Choice SPC – Global Superior Choice Fund 1 SP and Foresight Orient Global Superior Choice SPC – Vision Fund 1 SP agreed to subscribe for H Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$5,000,000;
- (g) a cornerstone investment agreement dated January 21, 2021 entered into among the Company, CLSA Capital Markets Limited (中信里昂證券資本市場有限公司), CLSA Limited (中信里昂證券有限公司) and LAKE BLEU PRIME HEALTHCARE MASTER FUND LIMITED pursuant to which LAKE BLEU PRIME HEALTHCARE MASTER FUND LIMITED agreed to subscribe for H Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$20,000,000;
- (h) a cornerstone investment agreement dated January 21, 2021 entered into among the Company, CLSA Capital Markets Limited (中信里昂證券資本市場有限公司), CLSA Limited (中信里昂證券有限公司) and WinTwin Capital Limited pursuant to which WinTwin Capital Limited agreed to subscribe for H Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$10,000,000;
- (i) a cornerstone investment agreement dated January 21, 2021 entered into among the Company, CLSA Capital Markets Limited (中信里昂證券資本市場有限公司), CLSA Limited (中信里昂證券有限公司) and IvyRock Asset Management (HK) Limited (常春藤資產管理(香港)有限公司) (as discretionary investment manager or discretionary asset manager for and on behalf of Ivyrock China Focus Master Fund, IvyRock China Equity Master Fund and Asia Series 6) pursuant to which IvyRock Asset Management (HK) Limited (常春藤資產管理(香港)有限公司) (as discretionary investment manager or discretionary asset manager for and on behalf of Ivyrock China Focus Master Fund, IvyRock China Equity Master Fund and Asia Series 6) agreed to subscribe for H Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$5,000,000; and
- (j) the Hong Kong Underwriting Agreement.


2. Our Intellectual Property Rights

(i) Trademarks


As of the Latest Practicable Date, our Group have registered the following trademarks which we considered to be or may be material to our business:

No.	Trademark	Class	Registered Owner	Place of Registration	Registration Number	Expiration Date
1.	PGT-One	42	Basecare Medical Device	PRC	39457127A	June 13, 2030
2.	PGTONE	42	Basecare Medical Device	PRC	38160304A	March 6, 2030
3.	BaseonePGT	5	Basecare Medical Device	PRC	37566713	December 13, 2029
4.	BasePGT-SR	5	Basecare Medical Device	PRC	33909600	July 6, 2029
5.	BasePGT-M	5	Basecare Medical Device	PRC	33909598	July 6, 2029
6.	BasePGT-A	5	Basecare Medical Device	PRC	33909596	July 6, 2029
7.	BaseWES	5	Basecare Medical Device	PRC	31969915	March 20, 2029
8.	BasePGT	5	Basecare Medical Device	PRC	31969914	March 20, 2029
9.	BasePGH	5	Basecare Medical Device	PRC	31969913	March 20, 2029
10.	BaseNIPS	5	Basecare Medical Device	PRC	31969911	March 27, 2029
11.	OnePGT	42	Basecare Medical Device	PRC	31969906	April 20, 2029
12.	BaseGCS	42	Basecare Medical Device	PRC	27795792	November 20, 2028

No.	Trademark	Class	Registered Owner	Place of Registration	Registration Number	Expiration Date
13.	BaseMGD	5	Basecare Medical Device	PRC	31969910	March 27, 2029
14.	BaseAI	9	Basecare Medical Device	PRC	27795784	November 20, 2028
15.	BaseCNV	5	Basecare Medical Device	PRC	25254076	July 6, 2028
16.	BaseNGD	5	Basecare Medical Device	PRC	25083408	June 27, 2028
17.	BasePGD	5	Basecare Medical Device	PRC	25083407	September 6, 2028
18.	贝康基因	9, 10, 36, 41, 42 and 44	Basecare Medical Device	PRC	19791511	August 13, 2027
19.	贝康医疗	9, 10, 41, 42 and 44	Basecare Medical Device	PRC	19791508	August 27, 2027
20.	贝康制造	10	Basecare Medical Device	PRC	19791507	August 13, 2027
21.	贝康咨询	44	Basecare Medical Device	PRC	19791506	August 13, 2027
22.	贝康投资	36	Basecare Medical Device	PRC	19791505	August 13, 2027
23.	BaseLIMS	5	Basecare Medical Device	PRC	17432099	September 13, 2026
24.	BasePGS	5	Basecare Medical Device	PRC	17431480	September 13, 2026
25.	BaseNIPT	5	Basecare Medical Device	PRC	17431479	September 13, 2026
26.	BaseNGS	5	Basecare Medical Device	PRC	17431478	September 13, 2026

No.	Trademark	Class	Registered Owner	Place of Registration	Registration Number	Expiration Date
27.		5	Basecare Medical Device	PRC	17431477	September 27, 2027
28.	Basecare	42	Basecare Medical Device	PRC	44377132	November 13, 2030

As of the Latest Practicable Date, our Group has applied for the registration of the following trademark which we consider to be material to our business:

No.	Trademark	Class	Applicant	Place of Application	Application Number	Date of Application
1.		10	Our Company	Hong Kong	305380083	September 4, 2020

(ii) *Patents*

As of the Latest Practicable Date, we had 18 registered patents and 48 pending patent applications:

No.	Patent	Patent Number	Type	Registered Owner	Place of Registration	Expiration Date
1.	A kind of cell culture fluid quality determining method based on raman spectroscopy measurement (一種基於拉曼光譜測量的細胞培養液品質檢測方法)	ZL201710227963.9	Invention	Basecare Medical Device	PRC	April 9, 2037
2.	A method of improving fetus dissociative DNA accounting in pregnant woman blood plasma dissociative DNA sequencing library (一種提高孕婦血漿遊離DNA測序文庫中胎兒遊離DNA佔比的方法)	ZL201610243399.5	Invention	Basecare Medical Device	PRC	April 18, 2036

No.	Patent	Patent Number	Type	Registered Owner	Place of Registration	Expiration Date
3.	Chromosome specific loci screening method and application thereof (一種染色體特異位點的篩選方法及應用)	ZL201310098346.5	Invention	Basecare Medical Device	PRC	March 25, 2033
4.	Determination method of fetal DNA content in maternal plasma, based on single-nucleotide polymorphic loci (一種基於單核苷酸多態性位點的孕婦血漿中胎兒DNA含量的測定方法)	ZL201310098730.5	Invention	Basecare Medical Device	PRC	March 25, 2033
5.	Cryopreservation disk (凍存盤)	ZL201921484202.2	Utility model	Basecare Medical Device	PRC	September 5, 2029
6.	Suction device (吸取裝置)	ZL201921484681.8	Utility model	Basecare Medical Device	PRC	September 5, 2029
7.	Clamping device (夾取裝置)	ZL201921484962.3	Utility model	Basecare Medical Device	PRC	September 5, 2029
8.	Raman spectrum detection system (拉曼光譜檢測收集系統)	ZL201820647127.6	Utility model	Basecare Medical Device	PRC	May 2, 2028
9.	Raman spectroscopy detection sample pool (拉曼光譜檢測樣品池)	ZL201820647592.X	Utility model	Basecare Medical Device	PRC	May 2, 2028
10.	Sample introduction device for Raman spectrum detection (拉曼光譜檢測進樣裝置)	ZL201820602710.5	Utility model	Basecare Medical Device	PRC	April 24, 2028
11.	Raman spectrum enhancing system for ultra-micro quantity of fluid (一種適用於極微量液體的拉曼光譜信號增強系統)	ZL201721494004.5	Utility model	Basecare Medical Device	PRC	November 9, 2027

No.	Patent	Patent Number	Type	Registered Owner	Place of Registration	Expiration Date
12.	Sampling box for hearing loss gene detection (一種耳聾基因檢測採樣盒)	ZL201621093135.8	Utility model	Basecare Medical Device	PRC	September 28, 2026
13.	Raman spectrometer (拉曼光譜儀)	ZL201730530754.2	Appearance design	Basecare Medical Device	PRC	October 31, 2027
14.	Sampling Box (China Deafness Genome Project) (採樣盒(中國聾病基因組計畫))	ZL201630488514.6	Appearance design	Basecare Medical Device	PRC	September 28, 2026
15.	Automated biological sample library (自動化生物樣本庫)	ZL201910948028.0	Invention	Basecare Medical Device	PRC	October 7, 2039
16.	Transfer container for biological samples (生物樣本中轉容器)	ZL202030193741.2	Appearance design	Basecare Medical Device	PRC	April 29, 2030
17.	Automatic storage equipment for biological samples (生物樣本自動化存儲設備)	ZL202030192790.4	Appearance design	Basecare Medical Device	PRC	April 29, 2030
18.	Biological sample storage tank (生物樣本儲存罐)	ZL202030231950.1	Appearance design	Basecare Medical Device	PRC	May 18, 2030

Our key patents that have been applied for registration are as follows:

No.	Patent	Application Number	Type	Applicant	Place of Application	Date of Application
1.	Method and device for constructing genotyping evaluation model for PGT-M detection (一種用於PGT-M檢測的基因分型評估模型的構建方法及裝置)	202010619134.7	Invention	Basecare Medical Device	PRC	July 1, 2020

No.	Patent	Application Number	Type	Applicant	Place of Application	Date of Application
2.	High-throughput sequencing-based reference material for detecting chromosome aneuploidy before embryo implantation and preparation method thereof (基於高通量測序的胚胎植入前染色體非整倍體檢測參考品及其製備方法)	202010060752.2	Invention	Basecare Medical Device	PRC	January 19, 2020
3.	Universal connector for multiple sequencing platforms, library construction method and kit suitable for multiple sequencing platforms (一種多測序平台通用接頭、適用於多測序平台的文庫構建方法及試劑盒)	201911424939.X	Invention	Basecare Medical Device	PRC	December 31, 2019
4.	Automated biological sample library (自動化生物樣本庫)	PCT/CN2019/121072	Invention	Basecare Medical Device	PRC	November 26, 2019
5.	Vitrification carrier (玻璃化冷凍載體)	PCT/CN2019/121073	Invention	Basecare Medical Device	PRC	November 26, 2019
6.	Automatic liquid nitrogen tank system (自動化液氮罐系統)	201910948044.X	Invention	Basecare Medical Device	PRC	October 8, 2019
7.	Temperature reduction and heat preservation device for realizing temperature partition (一種實現溫度分區的降溫保溫裝置)	201910948051.X	Invention	Basecare Medical Device	PRC	October 8, 2019
8.	Transfer container for biological samples (生物樣本中轉容器)	201910948053.9	Invention	Basecare Medical Device	PRC	October 8, 2019
9.	Vitrification carrier (玻璃化冷凍載體)	201910840190.0	Invention	Basecare Medical Device	PRC	September 6, 2019

No.	Patent	Application Number	Type	Applicant	Place of Application	Date of Application
10.	Primer composition, kit and application for genetic hearing loss gene detection before embryo implantation (胚胎植入前遺傳性耳聾基因檢測用引物組合物、試劑盒及應用)	201811060378.5	Invention	Basecare Medical Device	PRC	September 12, 2018
11.	Method for construct single cell high-throughput sequencing library and kit thereof (單細胞高通量測序文庫構建方法及其試劑盒)	201811150390.5	Invention	Basecare Medical Device	PRC	September 29, 2018
12.	Method, system, computer equipment and storage medium for managing biological sample library (生物樣本庫管理方法、系統、計算機設備和存儲介質)	201910806634.9	Invention	Basecare Medical Device	PRC	August 29, 2019
13.	Method for detecting quality of cell culture solution based on Raman spectrum measurement (一種基於拉曼光譜測量的細胞培養液品質檢測方法)	PCT/CN2018/072393	Invention	Basecare Medical Device	PRC	April 10, 2017
14.	Preimplantation chromosome abnormality detection kit (胚胎植入前染色體異常檢測試劑盒)	201710569713.3	Invention	Basecare Medical Device	PRC	July 13, 2017
15.	PCR primer set for reducing non-specific amplification and its application (用於減少非特異性擴增的PCR引物組及其應用)	202010929502.8	Invention	Basecare Medical Device	PRC	September 7, 2020
16.	A cryopreservation tube suction device for deep low temperature (一種用於深低溫的凍存管吸取裝置)	202010985920.9	Invention	Basecare Intelligent Manufacturing	PRC	September 18, 2020

No.	Patent	Application Number	Type	Applicant	Place of Application	Date of Application
17.	Method, device, computer equipment and storage medium for detecting medicinal properties of traditional Chinese medicine (檢測中藥藥性的方法、裝置、計算機設備和存儲介質)	202011001481.X	Invention	Basecare Medical Device; Obstetrics and Gynecology Hospital of Fudan University (復旦大學附屬婦產科醫院)	PRC	September 22, 2020
18.	An automated biological sample library for independently cooling (一種可獨立降溫的自動化生物樣本庫)	202011146618.0	Invention	Basecare Intelligent Manufacturing	PRC	October 23, 2020
19.	Temperature control method of automated biological sample library and automated biological sample library (自動化生物樣本庫的溫度控制方法和自動化生物樣本庫)	202011146615.7	Invention	Basecare Intelligent Manufacturing	PRC	October 23, 2020
20.	Liquid level sensor and liquid level detection system (液位傳感器及液位檢測系統)	202011170620.1	Invention	Basecare Intelligent Manufacturing	PRC	October 28, 2020
21.	A resistance type liquid level detection system (一種電阻式液位檢測系統)	202011173103.X	Invention	Basecare Intelligent Manufacturing	PRC	October 28, 2020
22.	Thermal insulation cabin and thermal insulation system convenient for manual intervention (一種便於人工干預的保溫艙及保溫艙系統)	202011245512.6	Invention	Basecare Intelligent Manufacturing	PRC	November 10, 2020
23.	A detachable liquid nitrogen tank rotating shaft structure (一種可拆卸的液氮罐轉軸結構)	202011319838.9	Invention	Basecare Intelligent Manufacturing	PRC	November 23, 2020

(iii) Software Copyrights

As of the Latest Practicable Date, we had registered the following software copyrights which we consider to be material to our business:

No.	Name	Copyright Owner	Registration Number	First Publication Date
1.	PGT-M intelligent classification evaluation system (PGT-M智能分型評估系統)	Basecare Medical Device	2020SR0502030	March 12, 2020
2.	IOS system of Xieyi 280 software (協醫280軟件IOS系統)	Basecare Medical Device	2019SR0074185	September 10, 2018
3.	Android system of Xieyi 280 software (協醫280軟體安卓系統)	Basecare Medical Device	2019SR0007449	September 10, 2018
4.	Haplotype linkage analysis system before embryo implantation (胚胎植入前單體型連鎖分析系統)	Basecare Medical Device	2018SR398365	February 10, 2018
5.	Genetic disease variation screening system (遺傳病變異篩選系統)	Basecare Medical Device	2018SR403452	February 10, 2018
6.	PGT-M data analysis and classification system (PGT-M數據分析及分型系統)	Basecare Medical Device	2020SR0521668	June 15, 2017
7.	Analysis and annotation system of copy number variation (CNV) data based on high-throughput sequencing (基於高通量測序的拷貝數變異數據分析及注釋系統)	Basecare Medical Device	2020SR0521444	June 15, 2016

No.	Name	Copyright Owner	Registration Number	First Publication Date
8.	Analysis and management system of chromosome aneuploidy detection data before embryo implantation (胚胎植入前染色體非整倍體檢測數據分析管理系統)	Basecare Medical Device	2018SR118913	February 1, 2016
9.	IOS system of Basecare 360 patient end software (貝康360患者端軟件IOS系統)	Basecare Medical Device	2020SR0786187	April 10, 2020
10.	Android system of Basecare 360 patient end software (貝康360患者端軟件安卓系統)	Basecare Medical Device	2020SR0787130	April 10, 2020
11.	Analysis and management system of chromosome aneuploidy detection data (染色體非整倍體檢測分析管理系統)	Our Company	2015SR045654	July 1, 2014
12.	Display software of DNA vector (DNA載體展示軟件)	Our Company	2012SR115177	April 5, 2012
13.	On-line design software of DNA vector (DNA載體在線設計軟件)	Our Company	2011SR059273	Not yet published
14.	Visualization software of DNA peak map (DNA峰圖可視化軟件)	Our Company	2011SR059272	Not yet published
15.	Chromosome abnormal Raman data intelligent analysis software based on embryo culture fluid (基於胚胎培養液的染色體異常拉曼數據智能分析軟件)	Basecare Medical Device	2018SR019968	September 17, 2017

No.	Name	Copyright Owner	Registration Number	First Publication Date
16.	Chromosome copy number variation recognition software based on chip data (基於芯片數據染色體拷貝數變異識別軟件)	Basecare Medical Device	2020SR1255877	June 12, 2020
17.	Genome copy number variant pathogenicity annotation software (基因組拷貝數變異致病性註釋軟件)	Basecare Medical Device	2020SR1255878	July 12, 2020
18.	Basecare ultra-low temperature storage system software (貝康超低溫存儲系統軟件)	Basecare Intelligent Manufacturing	2020SR1231212	July 30, 2020
19.	Deep cryogenic embryo automatic storage equipment control system (深低溫胚胎自動化存儲設備控制系統)	Basecare Intelligent Manufacturing	2020SR1236595	Not yet published

(iv) *Domain Names*

As of the Latest Practicable Date, we had registered the following domain names which we consider to be material to our business:

No.	Domain Name	Registered Owner	Date of Registration	Expiry Date
1.	biopgs.cn	Basecare Medical Device	May 3, 2016	May 3, 2023
2.	1000gene.com.cn	Basecare Medical Device	June 2, 2015	June 2, 2023
3.	1000gene.cn	Basecare Medical Device	June 2, 2015	June 2, 2023
4.	bioerp.com	Basecare Medical Device	January 10, 2013	January 10, 2023
5.	basecare.cn	Basecare Medical Device	December 19, 2012	December 19, 2022

C. FURTHER INFORMATION ABOUT OUR DIRECTORS, SUPERVISORS AND SUBSTANTIAL SHAREHOLDERS

1. Directors and Supervisors

(i) Disclosure of Interests – Interests and short positions of the Directors and the chief executive in the Shares, underlying Shares or debentures of our Company and our associated corporations

Immediately following completion of the Global Offering (assuming the Over-allotment Option is not exercised), the interests or short positions of our Directors and chief executives in the Shares, underlying Shares and debentures of our Company and its associated corporations, within the meaning of Part XV of the SFO, which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/she is taken or deemed to have under such provisions of the SFO), or which will be required, pursuant to section 352 of the SFO, to be recorded in the register referred to therein, or which will be required to be notified to our Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Companies contained in the Listing Rules, will be as follows:

Name	Position	Nature of interest	Number and class of Shares	Approximate percentage of interest in our Company	Approximate percentage of interest in the relevant class of Shares of our Company
Dr. Liang ⁽¹⁾	Executive Director and general manager	Beneficial owner Interest in controlled corporations	91,322,019 Domestic Shares	34.25%	47.42%
Mr. XU Wenbo (徐文博) ⁽²⁾	Non-executive Director	Interest in a controlled corporation	22,196,511 Domestic Shares	8.32%	11.53%

Notes:

- (1) As of the Latest Practicable Date, Basecare Investment was held as to approximately 58.31% by Dr. Liang (as the sole general partner). Therefore, Dr. Liang was deemed to be interested in the Shares in which Basecare Investment was interested under the SFO.
- (2) As of the Latest Practicable Date, Zhangjiagang Broad Vision Glory investment Partnership (Limited Partnership) (“**Broad Vision Glory**”, 張家港博華耀世投資合夥企業(有限合夥)) was the general partner of Broad Vision Investment. The general partner of Broad Vision Harmony was Zhangjiagang Broad Vision Evergreen investment Partnership (Limited Partnership) (“**Broad Vision Evergreen**”, 張家港博華常青投資合夥企業(有限合夥)). Both Broad Vision Glory and Broad Vision Evergreen were ultimately controlled by Mr. XU Wenbo (徐文博). Therefore, Mr. XU Wenbo was deemed to be interested in the Shares in which Broad Vision Investment and Broad Vision Harmony were interested under the SFO.

(ii) Particulars of service agreements

Pursuant to Rules 19A.54 and 19A.55 of the Listing Rules, our Company has entered into a service agreement with each of the Directors and Supervisors which contains provisions in relation to, among other things, compliance of relevant laws and regulations, observation of the Articles of Association and provisions on arbitration.

Each of the Directors and Supervisors has entered into a service agreement with our Company. The principal particulars of these service agreements are: (a) each of the agreements is for a term of three years following his/her respective appointment date; and (b) each of the agreements is subject to termination in accordance with their respective terms. The service agreements may be renewed in accordance with our Articles of Association and the applicable rules.

Save as disclosed above, our Company has not entered, and do not propose to enter, into any service contracts with any of the Directors or Supervisors in their respective capacities as Directors/Supervisors (other than contracts expiring or determinable by the employer within one year without the payment of compensation (other than statutory compensation)).

(iii) Directors' and Supervisors' remuneration

For details of the Directors' and Supervisors' remuneration, see "Directors, Supervisors and Senior Management—Remuneration of Directors, Supervisors and Five Highest Paid Individuals" of this prospectus and Note 8 to the Accountants' Report as set out in Appendix I to this prospectus.

2. Substantial Shareholders

For information on the persons who will, immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised), having or be deemed or taken to have beneficial interests or short position in our Shares or underlying Shares which would fall to be disclosed to our Company under the provisions of 2 and 3 of Part XV of the SFO, or directly or indirectly be interested in 10% or more of the issued voting shares of any other member of our Company, see "Substantial Shareholders" of this prospectus.

Save as disclosed in the section headed "Substantial Shareholders" in this prospectus, as of the Latest Practicable Date, our Directors were not aware of any persons who would, immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised), having or be deemed or taken to the beneficial interests or short position in our Shares or underlying Shares which would fall to be disclosed to our Company under the provisions of 2 and 3 of Part XV of the SFO, or directly or indirectly be interested in 10% or more of the issued voting shares of any member of our Group or had option in respect of such capital.

3. Disclaimers

Save as disclosed in this prospectus:

- (a) none of our Directors, Supervisors or any of the parties listed in “—7. Qualification of Experts” of this Appendix is:
 - (i) interested in our promotion, or in any assets which, within the two years immediately preceding the date of this prospectus, have been acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to our Company; or
 - (ii) materially interested in any contract or arrangement subsisting at the date of this prospectus which is significant in relation to our business;
- (b) save in connection with the Hong Kong Underwriting Agreement and the International Underwriting Agreement, none of the parties listed in “—7. Qualification of Experts” of this Appendix:
 - (i) is interested legally or beneficially in any shares in any member of our Group; or
 - (ii) has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for any securities in any member of our Group;
- (c) none of our Directors or Supervisors or their close associates or any shareholders of our Company who to the knowledge of our Directors owns more than 5% of our issued share capital has any interest in our top five customers or suppliers; and
- (d) none of our Directors or Supervisors is a director or employee of a company that has an interest in the share capital of our Company which, once the H Shares are listed on the Stock Exchange, would have to be disclosed pursuant to Divisions 2 and 3 of Part XV of the SFO.

D. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company or any of our subsidiaries.

2. Litigation

During the Track Record Period and as of the Latest Practicable Date, we were not engaged in any litigation, arbitration or claim of material importance and no litigation, arbitration or claim of material importance was known to our Directors to be pending or threatened by or against us, that would have a material adverse effect on our results of operations or financial conditions.

3. Sole Sponsor

The Sole Sponsor has made an application on behalf of our Company to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the H Shares to be converted from Unlisted Foreign Shares and the H Shares to be issued pursuant to the Global Offering (including the additional H Shares which may be issued pursuant to the exercise of the Over-allotment Option). All necessary arrangements have been made to enable our H Shares to be admitted into CCASS.

CLSA Capital Markets Limited, being the Sole Sponsor, satisfies the independence criteria applicable to sponsors set out in Rule 3A.07 of the Listing Rules.

The Sole Sponsor is entitled to a fee of USD500,000 for acting as our sponsor in connection with the Global Offering.

4. Compliance Advisor

Our Company have appointed Guotai Junan Capital Limited as our Compliance Advisor in compliance with Rule 3A.19 of the Listing Rules.

5. Preliminary Expenses

We have not incurred any material preliminary expenses in relation to the incorporation of our Company.

6. Taxation of holder of H Shares

The sale, purchase and transfer of H Shares are subject to Hong Kong stamp duty if such sale, purchase and transfer are effected on the H Share register of members of our Company, including in circumstances where such transaction is effected on the Stock Exchange. The current rate of Hong Kong stamp duty for such sale, purchase and transfer is a total of HK\$1.00 for every HK\$1,000 (or part thereof) of the consideration or, if higher, the fair value of the H Shares being sold or transferred. For further information in relation to taxation, see “Appendix III—Taxation and Foreign Exchange” to this prospectus.

7. Qualification of Experts

The following are the qualifications of the experts (as defined under the Listing Rules and the Companies (Winding Up and Miscellaneous Provisions) Ordinance) who have given opinions or advice which are contained in this prospectus:

Name	Qualification
CLSA Capital Markets Limited	Licensed to conduct type 4 (advising on securities) and type 6 (advising on corporate finance) of regulated activities under the SFO
KPMG	Certified public accountants, and Public Interest Entity Auditor registered in accordance with the Financial Reporting Council Ordinance
Tian Yuan Law Firm	PRC legal advisors and PRC IP counsel
Frost & Sullivan	Industry Consultant

8. Consent of Experts

Each of the experts whose names are set out in paragraph 7 above has given and has not withdrawn its consent to the issue of this prospectus with the inclusion of its report and/or letter and/or legal opinion (as the case may be) and references to its name included herein in the form and context in which it respectively appears.

9. Promoters

The promoters of our Company are all of the 16 then shareholders of our Company as of August 27, 2020 before our conversion into a joint stock limited liability company:

No.	Name
1.	Dr. Liang
2.	Basecare Investment
3.	Guangzhou DaAn Gene Technology Co., Ltd (廣州市達安基因科技有限公司)
4.	Guangzhou Darui
5.	Oriza Seed
6.	Zhejiang Shuangjing Investment Co., Ltd (浙江雙井投資有限公司)
7.	Suzhou Sungent
8.	Zhongcheng Fangyuan Phase II
9.	Guangzhou DaAn Jinghan Medical Health Industry Investment Enterprise (Limited Partnership) (廣州達安京漢醫療健康產業投資企業(有限合夥))
10.	Broad Vision Investment

No. Name

11. MING Bioventures
12. Yingtan Jinhu Jiayi Hongsheng Investment Management Limited Partnership Corporation (鷹潭金虎嘉怡弘晟投資管理有限合夥企業)
13. Hillhouse HK
14. Broad Vision Harmony
15. OPM
16. Ms. JI Dongmei (吉冬梅)

Save as disclosed in this prospectus, within the two years immediately preceding the date of this prospectus, no cash, securities or other benefit has been paid, allotted or given nor are any proposed to be paid, allotted or given to the promoters named above in connection with the Global Offering and the related transactions described in this prospectus.

10. Bilingual Prospectus

The English language and Chinese language versions of this prospectus are being published separately in reliance on the exemption provided in Section 4 of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

11. Binding Effect

This prospectus shall have the effect, if an application is made in pursuance of this prospectus, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of Sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance in so far as applicable.

12. No Material Adverse Change

Our Directors confirm that there has been no material adverse change in the financial or trading position or prospects of our Group since September 30, 2020 (being the date to which the latest audited consolidated financial statements of our Group were prepared).

13. Miscellaneous

Save as disclosed in this prospectus:

- (a) within the three years immediately preceding the date of this prospectus:
 - (i) no share or loan capital of our Company or any of our subsidiaries has been issued or agreed to be issued or is proposed to be fully or partly paid either for cash or a consideration other than cash;

- (ii) no commissions, discounts, brokerages or other special terms have been granted or agreed to be granted in connection with the issue or sale of any share or loan capital of our Company or any of our subsidiaries; and
- (iii) no commission has been paid or payable (except commission to sub-underwriters) to any persons for subscription, agreeing to subscribe, procuring subscription or agreeing to procure subscription of any shares of our Company or any of our subsidiaries;
- (b) no share or loan capital of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option;
- (c) no founder, management or deferred shares of our Company or any of our subsidiaries have been issued or agreed to be issued;
- (d) there is no arrangement under which future dividends are waived or agreed to be waived;
- (e) there has not been any interruption in the business of our Company which may have or have had a material adverse effect on the financial position of our Company in the 12 months immediately preceding the date of this prospectus;
- (f) our Company has no outstanding convertible debt securities or debentures; and
- (g) none of our equity and debt securities is presently listed on any stock exchange or traded on any trading system and no such listing or permission to list is being or is proposed to be sought.